Investigational drug · Phase 3
R-DXd
Also called: DS 6000a, MK-5909, raludotatug deruxtecan
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
10
10 still active
All registered trials
12
Any phase or sponsor naming "R-DXd"
First trial start
2021
Aug 19, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "R-DXd", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cancer
- Small Cell Lung Carcinoma
- Ovarian Neoplasms
- Solid Cancer
- Advanced Solid Tumor
- Metastatic Solid Tumors
- Ovarian Cancer Recurrent
- Lung Neoplasm
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "R-DXd" as an intervention, largest first.
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06161025 · 860 participants (planned) · Start Feb 27, 2024 · Primary completion Feb 29, 2028
Drug: R-DXd; Paclitaxel and 2 more · For: Solid Cancer
Sites: Anchorage, Alaska; New Haven, Connecticut; Coral Gables, Florida · 167 sites in all
- A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07776691 · 802 participants (planned) · Start Sep 18, 2026 · Primary completion Mar 19, 2032
Drug: R-DXd; Bevacizumab · For: Ovarian Cancer; Ovarian Neoplasms; Peritoneal Cancer and 1 more
Sites: Washington D.C., District of Columbia; Burlington, Massachusetts; Columbus, Ohio · 18 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07743164 · 646 participants (planned) · Start Oct 7, 2026 · Primary completion Aug 31, 2031
Drug: R-DXd; Bevacizumab and 4 more · For: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Sites: Fountain Valley, California; Orlando, Florida; Burlington, Massachusetts · 9 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06843447 · 605 participants (planned) · Start Apr 15, 2025 · Primary completion Mar 27, 2029
Drug: Raludotatug Deruxtecan; Carboplatin and 7 more · For: Ovarian Cancer Recurrent
Sites: New Haven, Connecticut; Louisville, Kentucky; Shreveport, Louisiana · 42 sites in all
- A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)Pivotal-lookingNot yet recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07791732 · 600 participants (planned) · Start Mar 31, 2027 · Primary completion Jul 1, 2029
Drug: R-DXd; Bevacizumab · For: Fallopian Tube Cancer; Primary Peritoneal Cancer; High-Grade Serous Ovarian Cancer and 1 more
- A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)Active, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06660654 · 335 participants (planned) · Start Jan 6, 2025 · Primary completion Dec 30, 2029
Drug: Raludotatug deruxtecan · For: Advanced Solid Tumor; Metastatic Solid Tumors
Sites: Marietta, Georgia; Ann Arbor, Michigan; East Brunswick, New Jersey · 48 sites in all
- A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)Pivotal-lookingTerminated
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT03248492 · 253 participants · Start Aug 25, 2017 · Primary completion Mar 21, 2019
Drug: DS-8201a · For: Breast Cancer
Sites: Anchorage, Alaska; Tucson, Arizona; Los Angeles, California · 99 sites in all
- A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT04707248 · 179 participants · Start Dec 22, 2020 · Primary completion Dec 30, 2026
Drug: DS-6000a; DS-6000a · For: Renal Cell Carcinoma; Ovarian Tumor
Sites: Tucson, Arizona; Denver, Colorado; Lake Mary, Florida · 13 sites in all
- A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06864169 · 160 participants (planned) · Start Apr 1, 2025 · Primary completion Aug 18, 2026
Drug: Raludotatug Deruxtecan (R-DXd) · For: Gastrointestinal Cancer
Sites: New Haven, Connecticut; Washington D.C., District of Columbia; Miami Beach, Florida · 41 sites in all
- Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06780098 · 144 participants (planned) · Start May 28, 2025 · Primary completion Mar 2, 2032
Drug: R-DXD; I-DXD and 3 more · For: Lung Neoplasm
Sites: Lexington, Kentucky; Baltimore, Maryland; Dallas, Texas · 46 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A potential antibody-drug conjugate targeting CDH6 (R-DXd) for chemo-resistant recurrent ovarian cancer.
Wang PH, Chang WH, Yang ST · Taiwan J Obstet Gynecol 2026
- Novel antibody-drug conjugates based on DXd-ADC technology.
Chen R, Ren Z, Bai L, et al. · Bioorg Chem 2024
- Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models.
Suzuki H, Nagase S, Saito C, et al. · Mol Cancer Ther 2024
Also in development for Fallopian Tube Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- H2 receptor antagonistPhase 34 trials
Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer
- ZN-c3azenosertibPhase 34 trials
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma
- H1 receptor antagonistPhase 33 trials
Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer
- HS-20089Phase 33 trials
Hansoh BioMedical R&D Company · Ovarian Cancer, Platinum-sensitive Recurrent Ovarian Cancer, Fallopian Tube Cancer
- IBI354Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Locally Advanced Unresectable or Metastatic Solid Tumors, Ovarian, Primary Peritoneal
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.